<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01104649</url>
  </required_header>
  <id_info>
    <org_study_id>FARM7KAJM7</org_study_id>
    <nct_id>NCT01104649</nct_id>
  </id_info>
  <brief_title>Efficacy of Riluzole in Hereditary Cerebellar Ataxia</brief_title>
  <official_title>Efficacy of Riluzole in Hereditary Cerebellar Ataxia: a Randomized Double-blind Placebo-controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>S. Andrea Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Agenzia Italiana del Farmaco</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>S. Andrea Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hereditary cerebellar ataxias include diverse neurodegenerative disorders. Hereditary
      ataxias can be divided into autosomal dominant ataxias (ADCAs), autosomal recessive ataxias
      (ARCAs), X-linked, and mitochondrial ataxias on the basis of mode of inheritance. The key
      feature in all these disorders is ataxia typically characterised by poor balance, hand
      incoordination, postural or kinetic tremor, dysarthria and dysphagia.

      To date no treatment has been shown to slow progression of the disease and symptomatic
      therapies are limited to few options that are partially effective.

      Purkinje cells project inhibitory signals to the deep cerebellar nuclei(DCN) which have a
      critical role in cerebellar function and motor performance. DCN neurons fire spontaneously in
      the absence of synaptic input from Purkinje neurons and modulation of the DCN response by
      Purkinje input is believed to be responsible for coordination of movement, while uncontrolled
      spontaneous firing of DCN neurons may underlay cerebellar ataxia. Recent studies have
      demonstrated that small-conductance calcium-activated potassium (SK) channels inhibitor are
      able to increase DCN firing rate. Since SK channels are critical regulators of DCN firing
      rate, SK openers such as the drug riluzole may reduce neuronal hyperexcitability and thereby
      be useful in the therapy of cerebellar ataxia.

      On this base the investigators published a pilot study in patients with chronic cerebellar
      ataxia (Ristori et al., Neurology 2010) investigating safety and efficacy of riluzole or
      placebo administration for 8 weeks. The results demonstrated a significative improvement in
      International Cooperative Ataxia Rating Scale (ICARS) global score after four weeks and after
      8 weeks in the riluzole arm.

      The present protocol is aimed at verifying the safety and efficacy of riluzole administration
      for a longer period, in a larger sample size of patients, with more stringent diagnostic
      criteria (hereditary cerebellar ataxia), respect to the above pilot study. Sixty patients
      will be enrolled in a double-blind, placebo-controlled trial. By central randomisation,
      patients will take 50 mg of riluzole or placebo twice daily for 12 months. Treatment effects
      will be assessed by comparing the Scale for the Assessment and Rating of Ataxia (SARA) before
      treatment and during therapy at months 3 and 12.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Scale for the assessment and rating of ataxia (SARA)</measure>
    <time_frame>12 months</time_frame>
    <description>Improvement in ataxia</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Baropodometric parameters</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>12 months</time_frame>
    <description>SF-36</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depression</measure>
    <time_frame>12 months</time_frame>
    <description>Beck Scale</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Cerebellar Ataxia</condition>
  <arm_group>
    <arm_group_label>Riluzole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Riluzole 50 mg is administered orally every 12 hours for 12 months (a 2:1 ratio for SCA/FA in the stratified randomization procedure)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo comparator</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo is administered orally every 12 hours for 12 months (a 2:1 ratio for SCA/FA in the stratified randomization procedure)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>riluzole</intervention_name>
    <description>Study drug will be orally dispensed in doses of 50 mg twice daily for 12 months.</description>
    <arm_group_label>Riluzole</arm_group_label>
    <other_name>Rilutek</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo comparator</intervention_name>
    <description>Study drug will be orally dispensed in doses of 50 mg twice daily for 12 months.</description>
    <arm_group_label>Placebo comparator</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with genetically confirmed diagnosis of hereditary cerebellar ataxia

        Exclusion Criteria:

          -  Concomitant experimental therapy for ataxia

          -  Serious systemic illnesses

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Silvia Romano, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Center for Experimental Neurological Therapies (CENTERS), S. Andrea Hospital, II Faculty of Medicine, &quot;Sapienza&quot; University of Rome</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Center for Experimental Neurological Therapies (CENTERS), S. Andrea Hospital, II Faculty of Medicine, &quot;Sapienza&quot; University of Rome</name>
      <address>
        <city>Rome</city>
        <zip>00139</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Ristori G, Romano S, Visconti A, Cannoni S, Spadaro M, Frontali M, Pontieri FE, Vanacore N, Salvetti M. Riluzole in cerebellar ataxia: a randomized, double-blind, placebo-controlled pilot trial. Neurology. 2010 Mar 9;74(10):839-45. doi: 10.1212/WNL.0b013e3181d31e23.</citation>
    <PMID>20211908</PMID>
  </reference>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 7, 2010</study_first_submitted>
  <study_first_submitted_qc>April 14, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2010</study_first_posted>
  <last_update_submitted>April 20, 2015</last_update_submitted>
  <last_update_submitted_qc>April 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>S. Andrea Hospital</investigator_affiliation>
    <investigator_full_name>Giovanni Ristori</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Spinocerebellar ataxia</keyword>
  <keyword>Friedreich ataxia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ataxia</mesh_term>
    <mesh_term>Cerebellar Ataxia</mesh_term>
    <mesh_term>Spinocerebellar Degenerations</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Riluzole</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>January 5, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

